Shanghai, China

Zhu Xie

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Chinese Academy of Sciences, Topharman Shanghai Co., Ltd.. Active years: 2016.


 

Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Zhu Xie: Innovator in Pharmaceutical Chemistry

Introduction

Zhu Xie is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on pyrazolopyrimidinone compounds. His research has led to advancements in the preparation and application of these compounds in pharmaceutical compositions.

Latest Patents

Zhu Xie holds a patent for a novel invention titled "Salt and polymorph of pyrazolopyrimidinone compound, and pharmaceutical composition containing the same, preparation method and use thereof." This patent relates to new salts of pyrazolopyrimidinone represented by a specific formula, along with various pharmaceutically acceptable forms. The invention also covers the preparation methods and potential uses of these compounds in pharmaceutical applications.

Career Highlights

Throughout his career, Zhu Xie has worked with notable organizations, including Topharman Shanghai Co., Ltd. and the Chinese Academy of Sciences. His experience in these institutions has allowed him to develop and refine his expertise in pharmaceutical research and innovation.

Collaborations

Zhu Xie has collaborated with esteemed colleagues such as Jianfeng Li and Guanghui Tian. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Zhu Xie's contributions to pharmaceutical chemistry and his innovative patents highlight his role as a key figure in the field. His work continues to influence the development of new pharmaceutical compositions and methods.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…